Sascha Haubner, MD (left)
Assistant Professor of Medicine
Department of Medicine, Hematology & Oncology
Program: Precision Oncology and Systems Biology (POSB)
Title: "Calibrated T cell engineering to safely target acute myeloid leukemia"
Description: Chimeric antigen receptor (CAR) therapy has yielded remarkable outcomes in B cell acute lymphoblastic leukemia, but re-directing conventional CAR designs against myeloid antigens has been complicated by myeloablation and early relapses in acute myeloid leukemia patients. In this talk, I will discuss our recent advances in using logic-gated approaches, cooperative CAR targeting and cytokine engineering to more effectively drive CAR T activity against AML without harming normal hematopoietic cells. I will further demonstrate how humanized mouse models can be utilized to pre-clinically model CAR-associated hematological toxicities and to de-risk novel CAR designs for eventual clinical translation.
Matthew Gallitto, MD, PhD (right)
Assistant Professor of Radiation Oncology at the Columbia University Medical Center
Department of Radiation Oncology
Program: Tumor Biology and Microenvironment (TBM)
Title: "From Radiation to Delivery: Novel Therapeutic Strategies for Pediatric Diffuse Midline Glioma"
Description: Diffuse midline glioma (DMG) is a devastating pediatric brain tumor with a near 100 percent fatality rate. Radiation therapy (RT) is the only upfront standard treatment despite providing only transient benefit. A major obstacle to therapeutic progress is the intact blood–brain barrier (BBB), which limits effective drug delivery to infiltrative tumor cells within the brainstem. In this talk, I will discuss strategies to overcome the BBB by combining RT with targeted drug delivery approaches. I will highlight emerging clinical and preclinical efforts using focused ultrasound and convection-enhanced delivery to improve intratumoral drug penetration, and describe how molecular profiling and network-based drug prediction algorithms can identify the next-generation of radiosensitizers. Together, these approaches illustrate a framework for coupling precision drug delivery with the only upfront standard of care, RT, to advance translational therapies for pediatric DMG.
Zoom information
https://columbiacuimc.zoom.us/j/98062087107?pwd=ODN1TFwbtR23dO0Pk7Bq73td7fG91L.1
Meeting ID: 980 6208 7107
Passcode: 267022
